Search clinical trials for: Open-label extension study

Total 120291 results

Novartis Pharmaceuticals

Recruiting

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) (REPLENISH-EXT)

Polymyalgia Rheumatica

Australia
GB002, Inc.

Not yet recruiting

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

Pulmonary Arterial Hypertension

United States
Ichnos Sciences SA

Not yet recruiting

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Australia
Ichnos Sciences SA

Recruiting

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States, Australia
GlaxoSmithKline
Iqvia Pty Ltd

Recruiting

An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) (AGILE)

Asthma

United States, Australia, Canada, France, Germany, Italy, Japan, Poland, Spain, China, Czechia, Hungary, Taiwan, United Kingdom
GB002, Inc., a wholly owned subsidiary of Gossamer...

Recruiting

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United States, Australia, Spain, Czechia, France, Germany, United Kingdom, Belgium
ES Therapeutics Australia Pty Ltd

Recruiting

Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy

Drug Resistant Epilepsy

Australia
Erydel

Recruiting

Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients With Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study (OLE-IEDAT)

Ataxia Telangiectasia

United States, Australia, Belgium, Germany, India, Italy, Poland, Spain, Tunisia
Scion NeuroStim

Enrolling by invitation

STEM-PD Open Label Extension (OLE)

Parkinson Disease | Parkinson's Disease and Parkinsonism

United States
Kezar Life Sciences, Inc.

Completed

Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.

Dermatomyositis | Polymyositis

United States, Czechia
Cytokinetics

Enrolling by invitation

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM (FOREST-HCM)

Symptomatic Hypertrophic Cardiomyopathy (HCM)

United States, France, Israel, Spain, United Kingdom, Italy, Portugal, Poland, Hungary, Denmark, Netherlands, Germany, Czechia
Clementia Pharmaceuticals Inc.

Completed

An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodysplasia Ossificans Progressiva

Australia, United States, Argentina, France, United Kingdom
Clene Nanomedicine

Active, not recruiting

An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS

Amyotrophic Lateral Sclerosis

Australia
Lupin Ltd.

Active, not recruiting

Open-label Extension Study in Paediatric Patients Who Have Completed the MEX-NM-301 Study.

Myotonic Disorders

France
Agenus Inc.

Active, not recruiting

Study of AGEN1571 in Participants With Advanced Solid Tumors

Advanced Solid Tumor

United States
Alladapt Immunotherapeutics, Inc.

Terminated

Open-label Extension Study of ADP101

Food Allergy

United States
Novartis Pharmaceuticals

Terminated

Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis

Lupus Nephritis

Czechia, Australia, Spain, Thailand, Brazil, Portugal, Vietnam, Korea, Republic of, Colombia, Guatemala, Slovakia, Philippines, Japan
AstraZeneca

Terminated

Open-label Extension Study of Brazikumab in Ulcerative Colitis (Expedition)

Ulcerative Colitis

Italy, United States, Taiwan, Germany, Poland, Israel, Puerto Rico, Czechia, South Africa, Japan, Korea, Republic of
Wave Life Sciences Ltd.

Terminated

Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)

ALS | FTD

Netherlands, United Kingdom
AstraZeneca

Terminated

Open-label Extension Study of Brazikumab in Crohn's Disease (INTREPID OLE)

Crohn's Disease | IBD

United States, Taiwan, Poland, Germany, South Africa
Merck Sharp & Dohme LLC

Completed

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study

Non-small Cell Lung Cancer

China
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Belgium, Canada, China, Czechia, Ireland, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study

Non-small Cell Lung Cancer
AstraZeneca

Terminated

A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

Spain, United States, Korea, Republic of, France, Portugal, Australia, Italy
Versartis Inc.
Premier Research Group plc

Terminated

Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)

Adult Growth Hormone Deficiency (AGHD)
TrueBinding, Inc.

Active, not recruiting

A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease

Alzheimer's Disease

United States
Amgen

Terminated

Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta

Osteogenesis Imperfecta (OI)

Canada, Czechia, Spain, United Kingdom, United States, Italy, Hungary, Australia, Belgium, France, Germany, Poland
Ipsen

Completed

Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia

Cervical Dystonia

United States, Russian Federation
Clementia Pharmaceuticals Inc.

Completed

An Open-Label Extension Study of Palovarotene to Prevent Heterotopic Ossification in People With Fibrodysplasia Ossificans Progressiva (FOP) in France

Fibrodysplasia Ossificans Progressiva

France
GlaxoSmithKline

Active, not recruiting

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

Breast Neoplasms | Ovarian Neoplasms

United States, Austria, Denmark, Spain, Canada, France, Israel, Italy
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis
Wave Life Sciences Ltd.

Terminated

Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

Huntington Disease

Denmark, Australia, Canada, France, United Kingdom, Germany, Poland
Prilenia

Completed

Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease (OPEN-HART)

Huntington Disease
Wave Life Sciences Ltd.

Terminated

Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

Huntington Disease

Denmark, Australia, Canada, France, United Kingdom, Germany, Poland
Novartis Pharmaceuticals

Withdrawn

Open-label Extension Study for CLCZ696G2301 (PARADISE-MI)

Post Myocardial Infarction
Galderma R&D

Completed

Extension Study for 43USSA1705

Nasolabial Folds

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia

Schizophrenia

Italy
Pfizer

Completed

Open-label Extension Study Of RN624

Arthritis | Osteoarthritis | OA Knee Pain

United States
Novartis Pharmaceuticals

Completed

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Parkinson Disease | Parkinsonian Disorders | Movement Disorders | Dyskinesias | Anti-Dyskinesia Agents

Spain, United States, Austria, Switzerland, France, Germany, Italy, Canada, Hungary, Slovakia
Pfizer

Completed

Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.

Urinary Bladder, Neurogenic

Japan
GlaxoSmithKline
Bausch Health Americas, Inc.

Terminated

Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS

Epilepsy

United States
GlaxoSmithKline

Completed

Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial

Epilepsy

United States, Canada, Argentina, Brazil, Mexico
Insmed Incorporated

Completed

Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212

NTM Lung Infection Due to MAC
Bausch Health Americas, Inc.

Terminated

Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201

Hepatitis B, Chronic
ImmunoGen, Inc.

Completed

Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Bausch Health Americas, Inc.
Syneos Health

Completed

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

Chronic Idiopathic Constipation

United States, Canada
Novartis Pharmaceuticals

Completed

Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan

Severe Pulmonary Arterial Hypertension

Japan
Amgen

Completed

Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia (OSLER-2)

Hyperlipidemia and Mixed Dyslipidemia

United States, Canada, Denmark, France, Italy, Belgium, Czechia, Taiwan, Japan, Switzerland, Germany, United Kingdom, Korea, Republic of, Hong Kong, Netherlands, New Zealand, South Africa, Australia, Spain, Austria, Hungary, Russian... and more
Prothena Biosciences Ltd.

Terminated

Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis (OLE)

AL Amyloidosis

United States
Amgen

Completed

A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors

Cancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy

United States, Australia

Search clinical trials for: Open-label extension study

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations